RESUMO
In a randomized trial, we compared the efficacy and toxicity of azithromycin and ceftibuten once daily in the initial (empiric) therapy of proven or suspected community-acquired respiratory tract infections (CARTI) in 163 pediatric patients: 95.5% of those treated with azithromycin and 83.6% of those treated with ceftibuten were cured or improved. Streptococcus pneumoniae was more frequently eradicated in the azithromycin than in the ceftibuten group, whereas gram-negative bacilli were more susceptible to ceftibuten. Elimination rates for Staphylococcus aureus and Haemophilus influenzae were similar; adverse reactions did not differ in both arms. Thus, azithromycin was more effective but equally safe than ceftibuten in the initial therapy of pediatric CARTI.
Assuntos
Antibacterianos/administração & dosagem , Azitromicina/administração & dosagem , Cefalosporinas/administração & dosagem , Quimioterapia Combinada/administração & dosagem , Infecções Respiratórias/tratamento farmacológico , Adolescente , Antibacterianos/efeitos adversos , Azitromicina/efeitos adversos , Ceftibuteno , Cefalosporinas/efeitos adversos , Criança , Pré-Escolar , Infecções Comunitárias Adquiridas/tratamento farmacológico , Esquema de Medicação , HumanosRESUMO
Twenty-nine children with cystic fibrosis (CF) were investigated for quinolone-induced arthropathy. Magnetic resonance imaging (MRI) was performed in 14/14 children treated with ofloxacin or ciprofloxacin and in 10/15 of those never treated with quinolones. The frequency of pathologic MRI findings, concerning cartilage thickness, careful analysis of the cartilage structure, presence of edema, cartilage-bone borderline and the presence of fluid in joints did not show any difference between both groups. Thus the presence of quinolone-induced arthrotoxicity cannot be confirmed in this study.